Drug Profile
Research programme: proteasome inhibitors - Nereus Pharmaceuticals
Latest Information Update: 16 Jan 2014
Price :
$50
*
At a glance
- Originator Nereus Pharmaceuticals
- Class Lactones; Pyrroles
- Mechanism of Action Proteasome inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer